At 2:15 p.m. ET, Hertzel C. Gerstein, MD, MSc, FRCPC, will offer insight into the use of an exendin-based GLP-1 receptor agonist in people with type 2 diabetes and high cardiovascular risk.
Next at #ADA2021: Investigators to share first cardiovascular outcomes results from AMPLITUDE-O
